Opendata, web and dolomites

NIRCOThera SIGNED

Spatiotemporal, near-infrared light controlled carbon monoxide delivery for cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NIRCOThera project word cloud

Explore the words cloud of the NIRCOThera project. It provides you a very rough idea of what is the project "NIRCOThera" about.

release    strategy    time    ready    signaling    monoxide    rebr3    lipid    infiltrating    cardiovascular    relatively    body    components    tumours    carbon    inflammation    net4    gaseous    unexploited    near    metastasis    models    multiple    diseases    ultrahigh    disorders    dose    modulatory    realize    precision    toxicity    cells    co    consists    plan    platform    critical    reported    tumour    chemotherapeutics    shown    ros    nir       human    bifunctional    light    anti    nanotubes    immunomodulatory    conjugate    expression    triggered    spatiotemporal    loaded    impart    inflammatory    swcnts    effect    exogeneous    genes    stability    angiogenesis    releasing    activation    corms    vivo    manner    health    naturally    protein    combine    immune    eradicate    followed    progress    species    microenvironment    manipulate    functionalized    site    cancer    avenue    single    molecule    chemotherapy    exposure    biocompatibility    sites    molecules    chosen    excretion    intratumoural    rhenium    purpose    tissues    largely    fast    animal    reactive    progression    expecting    oxygen    clearance    dependent    therapeutic    cell    precise    walled    infrared       exclusively    profile    treatment    generation    herein    sensitivity   

Project "NIRCOThera" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

Carbon monoxide (CO) is a gaseous signaling molecule naturally produced by the human body. In recent years, CO has shown its anti-inflammatory and immunomodulatory properties and thus therapeutic potential in the treatment of inflammatory disorders and cardiovascular diseases. It is promising to exploit the modulatory effect of exogeneous CO in tumour microenvironment where inflammation and angiogenesis are the critical components of tumour progression and metastasis, which is largely unexploited. For this purpose, it is key to manipulate CO exposure in a precise dose and time-controlled manner exclusively at the tumour site. Herein, we propose to develop a new CO delivery avenue, enabling controlled CO release to tumour sites with spatiotemporal precision by using near infrared light (NIR). Specifically, the strategy consists of single-walled carbon nanotubes (SWCNTs) loaded with CO releasing molecules (CORMs). We have reported the development of a SWCNTs-based bifunctional system that enables intratumoural protein delivery and NIR activation, which is ready to be applied to realize controlled CO release in vivo. We plan to conjugate [ReBr3(CO)3][NEt4]2 to SWCNTs. The rhenium complex is chosen because of its stability and non-toxicity while the lipid functionalized SWCNTs have shown biocompatibility, ultrahigh tumour uptake and relatively fast clearance and excretion from the health tissues, which impart the platform promising for in vivo application. We will evaluate the stability of the platform, followed by the NIR-triggered CO release profile and then dose- and time-dependent effect on both cancer cells and tumour-infiltrating immune cells, including the generation of reactive oxygen species (ROS) and expression of multiple genes associated with tumour progress. Furthermore, expecting increased cancer cell sensitivity to chemotherapeutics with CO treatment, we will combine the proposed strategy with current chemotherapy to eradicate tumours in animal models.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NIRCOTHERA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NIRCOTHERA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More  

LUNG-BIM (2019)

Induction of B cell immunity in the lung mucosa

Read More